FHA
CRBP icon

Flagship Harbor Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Flagship Harbor Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16
Closed -$130 – 1007
2025
Q4 		$130 Buy
+16
New +$197 ﹤0.01% 2218

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Flagship Harbor Advisors's CRBP Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q1 2026, closing a stake of 16 shares — an estimated $130 sold.

Flagship Harbor Advisors first reported a position in CRBP in Q4 2025 and held it in 1 quarter. The position peaked at $130 in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Corbus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 16 Corbus Pharmaceuticals shares in Q1 2026, an estimated $130.
  • Flagship Harbor Advisors first reported a position in Corbus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Flagship Harbor Advisors's Corbus Pharmaceuticals position peaked at $130 in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.